Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Urogen Pharma Ltd URGN

Healthcare Biotechnology
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel... see more

Recent & Breaking News (NDAQ:URGN)

UroGen Pharma to Participate at Upcoming Investor Conferences

Business Wire 19 hours ago

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

Business Wire 2 days ago

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

Business Wire 3 days ago

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

Business Wire 3 days ago

UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

Business Wire 4 days ago

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

Business Wire April 17, 2024

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Business Wire April 15, 2024

UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals

Business Wire April 3, 2024

UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

Business Wire March 14, 2024

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 8, 2024

UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024

Business Wire March 4, 2024

UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference

Business Wire February 26, 2024

UroGen Pharma to Participate at Upcoming Investor Conferences

Business Wire February 1, 2024

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102

Business Wire January 24, 2024

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

Business Wire January 17, 2024

UroGen Pharma to Participate in the B. Riley Healthcare Conference

Business Wire January 11, 2024

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 8, 2023

UroGen Pharma Reports Third Quarter 2023 Financial Results

Business Wire November 14, 2023

UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology

Business Wire November 13, 2023

UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

Business Wire November 7, 2023